Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.

MLA

Stewart, Thomas G., et al. “Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.” JAMA, vol. 330, no. 24, Dec. 2023, pp. 2354–63. EBSCOhost, https://doi.org/10.1001/jama.2023.23363.

APA

Stewart, T. G., Rebolledo, P. A., Mourad, A., Lindsell, C. J., Boulware, D. R., McCarthy, M. W., Thicklin, F., Garcia Del Sol, I. T., Bramante, C. T., Lenert, L. A., Lim, S., Williamson, J. C., Cardona, O. Q., Scott, J., Schwasinger-Schmidt, T., Ginde, A. A., Castro, M., Jayaweera, D., Sulkowski, M., … Naggie, S. (2023). Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial. JAMA, 330(24), 2354–2363. https://doi.org/10.1001/jama.2023.23363

Chicago

Stewart, Thomas G, Paulina A Rebolledo, Ahmad Mourad, Christopher J Lindsell, David R Boulware, Matthew W McCarthy, Florence Thicklin, et al. 2023. “Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.” JAMA 330 (24): 2354–63. doi:10.1001/jama.2023.23363.